Everything below concerns Copper peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence found naturally in human plasma, saliva and urine. Loren Pickart reported the isolation of the free peptide in 1973 while studying factors that influenced the growth of aged liver cells in culture. The peptide was later shown to bind copper(II) with high affinity, and the metal-bound form became the focus of most subsequent research. Its concentration in circulation declines markedly with age, a pattern that is well documented, though the physiological consequences of that decline remain debated.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The compound entered scientific literature in the 1970s, when plasma factors with copper-binding activity were isolated and characterized. Later work expanded into wound healing, skin biology, and cosmetic formulation, where copper tripeptide-1 became a recognized ingredient name. Most published studies remain preclinical or small-scale, and findings are often reported in specialized dermatology or peptide journals. Regulatory treatment varies: some jurisdictions allow it as a cosmetic ingredient, while research-grade material is sold for laboratory use. Questions about optimal delivery, target tissues, and long-term effects continue to be investigated rather than settled.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
| Property | Value | Notes |
|---|---|---|
| INCI name | Copper tripeptide-1 | Standard designation on cosmetic ingredient labels |
| Peptide sequence | Gly-His-Lys | Three-residue ligand; binding occurs at the histidine side chain |
| Metal-to-peptide ratio | 1 to 1 | One copper(II) ion per peptide unit |
| Appearance | Blue to violet powder | Colour arises from copper-to-peptide electronic transitions |
| Water solubility | Freely soluble | Commonly formulated in aqueous or water-alcohol systems |
Published work on GHK-Cu concentrates largely on cell culture systems rather than whole organisms. Frequently used endpoints include collagen synthesis, expression of matrix metalloproteinases, and migration of fibroblasts. Some reports describe antioxidant behavior, while others stress delivery of copper into cells. These mechanisms are proposed rather than demonstrated, and the relative weight of each pathway is unclear. Human trials are few and generally small, so laboratory findings should not be read as confirmed clinical results.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide backbone consists of glycine, histidine, and lysine joined in that order. Copper is held through the imidazole nitrogen of histidine and the alpha-amino group at the N-terminus, which together produce a square-planar arrangement around the metal center. The solid appears blue to violet, a color that originates from d-d electronic transitions within the copper coordination sphere. The complex is indexed under CAS number 89030-95-5.
The sequence now called GHK was first reported in the early 1970s after isolation from human plasma, where it was noted to influence liver cell behavior in laboratory preparations. Later work described a copper-binding form and its activity in fibroblast and wound-model experiments. Review articles frequently group the substance with other copper peptides. Concentrations in blood appear to fall with age in several small surveys, although the reason for this trend is not settled. Whether such a decline carries functional consequences remains an open question.
Solutions of GHK-Cu respond strongly to pH, redox conditions, and the presence of competing chelators such as EDTA. Below roughly pH 4 the copper tends to dissociate, because the amide nitrogen donors become protonated and can no longer coordinate. Strongly alkaline conditions instead favour hydrolysis and precipitation of copper hydroxide. Dissolved oxygen and light accelerate breakdown of the peptide backbone, and the copper released during that process can catalyse further oxidation, so dry, cold, dark storage is the usual recommendation.
Routine characterisation relies on reversed-phase high-performance liquid chromatography for peptide purity, paired with mass spectrometry for identity confirmation. Ultraviolet-visible spectroscopy detects the metal centre through its absorption band in the visible region, and inductively coupled plasma mass spectrometry quantifies total copper so that a metal-to-peptide ratio can be calculated. Amino acid analysis confirms the expected residue composition. Together these techniques establish concentration, identity, and stoichiometry, but none of them directly reports biological activity.
Quality specifications for research material commonly state peptide purity, copper stoichiometry, counter-ion identity, and residual water content. Frequent counter-ions include acetate and trifluoroacetate, which differ in mass and in their effect on solubility and handling. Whether batch-to-batch differences in reported responses trace to these parameters or to assay conditions remains an open question, since published comparisons rarely control for all of them at once. Independent verification therefore normally pairs a purity measurement with an elemental copper measurement on the same lot.
Of these 39 odd Z elements, 30 elements (including hydrogen-1 where 0 neutrons is even) have one stable odd-even isotope, and nine elements: chlorine (17Cl), potassium (19K), copper (29Cu), gallium (31Ga), bromine (35Br), silver (47Ag), antimony (51Sb), iridium (77Ir), and thallium (81Tl), have two odd-even stable isotopes each. This makes a total 30 + 2(9) = 48 stable odd-even isotopes. There are also five primordial long-lived radioactive odd-even isotopes, 8737Rb, 11549In, 18775Re, 15163Eu, and 20983Bi. The last two were only recently found to decay, with half-lives greater than 1018 years.
== Efficacy and side effects == Just like cocaine, dimethocaine inhibits the uptake of dopamine in the brain by interfering with the dopamine transporters. The potency of these drugs is linked to their affinity for the dopamine transporters, and their potency to inhibit dopamine uptake. In studies with rhesus monkeys the affinity of dimethocaine for dopamine transporters is smaller than that of cocaine, whereas dimethocaine's potency to inhibit dopamine uptake is similar. This means that more of dimethocaine is needed to reach a similar response. The peak effects occurred within 10 to 20 minutes after the injection and decreased to baseline levels within an hour. Dimethocaine is often abused as a legal substitute for cocaine. The drug is administered intravenously or nasally, because ingestion would lead to rapid hydrolyzation. Its positive effects are euphoria, stimulation, increased talkativeness and mood lift. However, because the drug acts similar as cocaine, it has comparable negative side effects. These side effects include: tachycardia, difficulty with breathing, pain on the chest, vasoconstriction, insomnia, paranoia and anxiety. Dimethocaine probably poses larger health issues than cocaine. This is due to the fact that more dimethocaine must be administered to produce the same euphoric feeling, resulting in larger risk for the negative effects.
2000 – 2008 Member of the board of the Technical University of Denmark. 2000 – 2003 Member of the Academy of Technical Sciences, Denmark 2003 – 2004 President of the Academy of Technical Sciences, Denmark 2006 – 2012 Member of the board of Cellartis AB, Sweden 2012 – 2019 Member of the board of the University of Copenhagen (chairman from 2017 to 2020) 2014 - 2016 Chairman of the board, Steno Diabetes Center, Denmark 2018 - 2019 Board member, Symphogen A/S, Denmark 2020 - Member of the board of BB Biotech AG, Switzerland
== Effects on chronic pain == Data obtained from using P2 receptor-selective antagonists has produced evidence supporting ATP's ability to initiate and maintain chronic pain states after exposure to noxious stimuli. It is believed that ATP functions as a pronociceptive neurotransmitter, acting at specific P2X and P2Y receptors in a systemized manner, which ultimately (as a response to noxious stimuli) serve to initiate and sustain heightened states of neuronal excitability. This recent knowledge of purinergic receptors' effects on chronic pain provide promise in discovering a drug that specifically targets individual P2 receptor subtypes. While some P2 receptor-selective compounds have proven useful in preclinical trials, more research is required to understand the potential viability of P2 receptor antagonists for pain. Recent research has identified a role for microglial P2X receptors in neuropathic pain and inflammatory pain, especially the P2X4 and P2X7 receptors.
Partly to aid the Apollo missions, the Surveyor program was conducted by NASA, with five successful soft landings out of seven attempts from 1966 to 1968. The Lunar Orbiter program had five successes out of five attempts in 1966–1967. In late 1966, Luna 13 became the third spacecraft to make a soft-landing on the Moon, with the American Surveyor 1 having now taken second. Luna 13 made use of inflatable air-bags to soften it's landing. Surveyor 1 was a 995 kg lander, notably larger than the 112 kg Luna 13 E-6M lander. Surveyor 1 was equipped with a Doppler velocity sensing system that fed information into the spacecraft computer to implement a controllable descent to the surface. Each of the three landing pads also carried aircraft-type shock absorbers and strain gauges to provide data on landing characteristics, important for future Apollo missions. Surveyor 3, which successfully touched down on the Moon April 20, 1967, carried a 'surface sampler' which facilitated tests of the Lunar soil. Based on these experiments, scientists concluded that lunar soil had a consistency similar to wet sand, with a bearing strength of about 10 pounds per square inch (0.7 kilograms per square centimeter, or 98 kilopascals), which was concluded to be solid enough to support an Apollo Lunar Module. The Surveyor 3 lander would be later visited by Apollo 12 astronauts. On Nov. 17, 1967, before mission termination, Surveyor 6 fired its thrusters for 2.5 seconds, becoming the first spacecraft launched from the lunar surface.
Sources: en.wikipedia.org
As the United Kingdom agreed to the partitioning of India, the modern state of Pakistan was established on 14 August 1947 (27th of Ramadan in 1366 of the Islamic calendar, a holy time regarded as auspicious and noted for its religious importance). This new nation amalgamated the Muslim-majority eastern and northwestern regions of British India, comprising the provinces of Balochistan, East Bengal, the North-West Frontier Province, West Punjab, and Sindh. In the riots that accompanied the partition in Punjab Province, between 200,000 and 2,000,000 people were killed in what some have described as a retributive genocide between the religions. Around 50,000 Muslim women were abducted and raped by Hindu and Sikh men, while 33,000 Hindu and Sikh women experienced the same fate at the hands of Muslims. Around 6.5 million Muslims moved from India to West Pakistan and 4.7 million Hindus and Sikhs moved from West Pakistan to India. It was the largest mass migration in human history. A subsequent dispute over the princely state of Jammu and Kashmir eventually sparked the Indo-Pakistani War of 1947–1948.
=== Legal status === In October 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Cibinqo, intended for the treatment of atopic dermatitis. The applicant for this medicinal product is Pfizer Europe MA EEIG. In December 2021, the European Commission approved abrocitinib for the treatment of atopic dermatitis. In January 2022, the US Food and Drug Administration (FDA) approved abrocitinib for adults with moderate-to-severe atopic dermatitis.
=== 20th century === From the first half of the twentieth century, physicians used other substances as breast implant fillers—ivory, glass balls, ground rubber, ox cartilage, Terylene wool, gutta-percha, Dicora, polyethylene chips, Ivalon (polyvinyl alcohol—formaldehyde polymer sponge), a polyethylene sac with Ivalon, polyether foam sponge (Etheron), polyethylene tape (Polystan) strips wound into a ball, polyester (polyurethane foam sponge) Silastic rubber, and teflon-silicone prostheses. In the mid-twentieth century, Morton I. Berson, in 1945, and Jacques Maliniac, in 1950, each performed flap-based breast augmentations by rotating the patient's chest wall tissue into the breast to increase its volume. Furthermore, throughout the 1950s and the 1960s, plastic surgeons used synthetic fillers—including silicone injections received by some 50,000 women, from which developed silicone granulomas and breast hardening that required treatment by mastectomy. In 1961, the American plastic surgeons Thomas Cronin and Frank Gerow, and the Dow Corning Corporation, developed the first silicone breast prosthesis, filled with silicone gel; in due course, the first augmentation mammoplasty was performed in 1962 using the Cronin–Gerow Implant, prosthesis model 1963. In 1964, the French company Laboratoires Arion developed and manufactured the saline breast implant, filled with saline solution, and then introduced for use as a medical device in 1964.
Sanlúcar's name may have derived from the Arab šurūq (Arabic: شروق), the Arabic name for the Levant wind called sirocco or jaloque. According to the National Statistics Institute of Spain, the Sanlúcar toponym does not exist. However, there is historical mention of Brother Alfonso Sanlúcar de Barrameda, a Franciscan who was bishop of the Canaries-Rubicon in the period 1404–1417, and Fray Juan de Sanlúcar, a Franciscan who served in the same office from 1470–1474. As for the name Barrameda, it is unique to people born in the Canary Islands, according to census data from 1 January 2006. The historical relations between the House of Medina Sidonia, Sanlúcar, and the Canaries may explain the presence of these surnames in the Canaries. Barrameda was derived from bar-am-ma'ida, an Arabic phrase for "water well of the plateau".
In August 2006, the court accepted the settlement between RTM and Access Now. The result was that every year, 100 of the RTM stores would be retrofitted to comply with the ADA. Accordingly, it was estimated that about $1.2 million would be spent to retrofit those stores each year. In 2008, Triarc purchased Wendy's, and changed its name to Wendy's/Arby's Group, to reflect their core businesses. In January 2011, it was announced that Wendy's/Arby's Group was looking into selling the Arby's side of the business to focus on the Wendy's brand. It was officially announced the companies would split on January 21, 2011. In 2009, the Wendy's/Arby's Group signed a franchise deal with the Al Jammaz Group of Saudi Arabia to open dual-branded Wendy's/Arby's through the Middle East with the first location opening in Dubai in the United Arab Emirates in May 2010. The Wendy's/Arby's Group also signed a similar franchise deal in June 2010 with Tab Gida Sanayi ve Ticaret to open dual-branded restaurants in Turkey. After the split, the former Wendy's/Arby's Group became The Wendy's Company.
Sources: en.wikipedia.org
=== Secretion of Interleukin-10 === Genetically engineered L. lactis can secrete the cytokine interleukin-10 (IL-10) for the treatment of inflammatory bowel diseases (IBD), since IL-10 has a central role in downregulating inflammatory cascades and matrix metalloproteinases. A study by Lothar Steidler and Wolfgang Hans shows that in situ synthesis of IL-10 by genetically engineered L. lactis requires much lower doses than systemic treatments like antibodies to tumor necrosis factor (TNF) or recombinant IL-10. The authors propose two possible routes by which IL-10 can reach its therapeutic target. Genetically engineered L. lactis may produce murine IL-10 in the lumen, and the protein may diffuse to responsive cells in the epithelium or the lamina propria. Another route involves L. lactis being taken up by M cells because of its bacterial size and shape, and the major part of the effect may be due to recombinant IL-10 production in situ in intestinal lymphoid tissue. Both routes may involve paracellular transport mechanisms that are enhanced in inflammation. After transport, IL-10 may directly downregulate inflammation. In principle, this method may be useful for intestinal delivery of other protein therapeutics that are unstable or difficult to produce in large quantities and an alternative to the systemic treatment of IBD.
Glucagon/gastric inhibitory polypeptide/secretin/vasoactive intestinal peptide hormones are a family of evolutionarily related peptide hormones that regulate activity of G-protein-coupled receptors from the secretin receptor family. A number of polypeptidic hormones, mainly expressed in the intestine or the pancreas, belong to a group of these structurally related peptides. This family of hormones are produced from (preproglucagon), which is cleaved to produce glucagon, glucagon-like protein I, glucagon-like protein II, and glicentin. Other members of the structurally similar group include secretin, gastric inhibitory peptide, vasoactive intestinal peptide, prealbumin, peptide HI-27, and growth hormone releasing factor. One hormone, glucagon, is fully conserved in all mammalian species in which it has been studied.
After World War I, the victors settled border changes. The Treaty of Saint-Germain of 1919 ruled according to the 1915 London Pact, that the southern part of the Austrian crown land of Tyrol had to be ceded to the Kingdom of Italy, including the territory of the former Trent bishopric, roughly corresponding to the modern-day Trentino, as well as the south of the medieval Tyrol county, the present-day province of South Tyrol. Italy thus took control of the strategically important Alpine water divide at the Brenner Pass and over the south of Tyrol proper with its large German-speaking majority. Since 1949 both parts form the autonomous Italian Trentino-Alto Adige/Südtirol region. The northern part of Tyrol retained by the First Austrian Republic today forms the Austrian State of Tyrol with its East Tyrol exclave. In 1945 following World War II, Austrian attempts and South Tyrolean petitions to reunite South Tyrol with Austria were unsuccessful; Italy retained control. From 1972 onwards, the Italian Republic has granted further autonomy to the Trentino-Alto Adige/Südtirol region.
== Inhibitors == Glycogen synthase kinase inhibitors are different chemotypes and have variable mechanisms of action; they may be cations, from natural sources, synthetic ATP and non-ATP competitive inhibitors and substrate-competitive inhibitors. GSK3 is a bi-lobar architecture with N-terminal and C-terminal, the N-terminal is responsible for ATP binding and C-terminal which is called as activation loop mediates the kinase activity, Tyrosine located at the C-terminal it essential for full GSK3 activity.
Until the time of Napoleon, European states employed relatively small armies, made up of both national soldiers and mercenaries. These regulars were highly drilled, professional soldiers. Ancien Régime armies could only deploy small field armies due to rudimentary staffs and comprehensive yet cumbersome logistics. Military innovators in the mid-18th century began to recognise the potential of an entire nation at war: a "nation in arms". The scale of warfare dramatically enlarged during the Revolutionary and subsequent Napoleonic Wars. During Europe's major pre-revolutionary war, the Seven Years' War of 1756–1763, few armies ever numbered more than 200,000 with field forces often numbering less than 30,000. The French innovations of separate corps (allowing a single commander to efficiently command more than the traditional command span of 30,000 men) and living off the land (which allowed field armies to deploy more men without requiring an equal increase in supply arrangements such as depots and supply trains) allowed the French republic to field much larger armies than their opponents. Napoleon ensured during the time of the French republic that separate French field armies operated as a single army under his control, often allowing him to substantially outnumber his opponents. This forced his continental opponents to also increase the size of their armies, moving away from the traditional small, well-drilled Ancien Régime armies of the 18th century to mass conscript armies.
Sources: en.wikipedia.org
It is a complex of a three-amino-acid peptide, glycine, histidine and lysine, bound to a single copper(II) ion. The metal is held mainly by the histidine side chain and the peptide backbone. Most commercial material is supplied as an acetate salt rather than as the free complex.
The free peptide was reported in 1973 by Loren Pickart, who isolated it from human plasma. Its copper-binding behaviour was characterised over the following years. The metal-bound form has been the subject of most later research.
Yes. Copper tripeptide-1 is the name used in cosmetic ingredient labelling, while GHK-Cu is the shorthand found in the scientific literature. Both refer to the same peptide-copper complex, and the two terms are interchangeable in most technical documents.
GHK-Cu is a complex of the tripeptide glycyl-L-histidyl-L-lysine with copper(II). The peptide binds copper through its histidine residue and neighboring amide nitrogens, forming a stable coordination compound. It is studied as a research chemical and used in some cosmetic formulations.